kif22 Antibody

What is KIF22 and what cellular functions does it perform?

KIF22, also known as kinesin-like DNA-binding protein (Kid) or KNSL4, is a member of the kinesin superfamily proteins (KIFs) that binds to both microtubules and DNA . KIF22 plays crucial roles in spindle formation and chromosome movements during mitosis and meiosis . Functionally, it is involved in the congression of laterally attached chromosomes in NDC80-depleted cells and is essential for proper chromosome segregation . KIF22 is highly expressed in proliferating tissues, particularly in chondrocytes at the proliferative zone of growth plate cartilage, suggesting tissue-specific functions . Research has demonstrated that KIF22 is essential for cell proliferation, with knockdown studies showing reduced growth rates and decreased numbers of mitotic cells without affecting apoptosis .

What detection methods are most effective for studying KIF22 expression?

Several complementary approaches provide robust detection of KIF22:

For optimal results, researchers should confirm KIF22 antibody specificity using knockout controls, as demonstrated in HEK-293T KIF22 knockout cell lines where anti-KIF22 antibody [EP2748] showed complete loss of signal .

Where is KIF22 predominantly expressed in normal tissues?

KIF22 shows tissue-specific expression patterns that correlate with its functional roles. Real-time qPCR analysis in mouse tissues has revealed that KIF22 mRNA is highly abundant in growth plate cartilage and bone marrow . Immunohistochemistry of tibia growth plate sections from 2-week-old mice demonstrated that KIF22 protein is predominantly detected in chondrocytes within the proliferative zone . Additionally, KIF22 protein was observed in cells within subchondral bone and in the marrow space . This expression pattern aligns with KIF22's role in regulating cell proliferation, particularly in tissues with high mitotic activity. When performing immunohistochemical detection of KIF22, researchers should consider these tissue-specific expression patterns for proper experimental controls.

How can alterations in KIF22 expression be accurately quantified in experimental models?

Accurate quantification of KIF22 expression requires standardized approaches that account for experimental variabilities:

For protein-level quantification, western blot analysis with appropriate loading controls is recommended. Studies have successfully used GAPDH as a normalization control for KIF22 expression . Image analysis software such as ImageJ can calculate the grayscale intensity (IntDen) of protein bands after subtracting background signal . When comparing expression across samples, researchers should:

• Load equal amounts of protein (typically 20-40 μg) per lane

• Include multiple biological replicates (minimum n=3)

• Normalize KIF22 signal to housekeeping controls

• Report fold-changes relative to control conditions

For tissue samples, semi-quantitative scoring systems have been developed. For example, in bladder cancer research, KIF22 expression has been classified based on staining intensity (0-3) and proportion of stained cells (0-3) . A composite staining index can be calculated by multiplying these scores (range 0-12), with 0 considered negative, 1-6 considered low expression, and 7-12 considered high expression . For reliable results, sections from each patient should be observed within multiple visual fields (typically five) and evaluated by an experienced pathologist .

What approaches can be used to study KIF22 dynamics during mitosis?

Studying KIF22 dynamics during mitosis requires specialized techniques that capture both spatial and temporal information:

Fluorescence Recovery After Photobleaching (FRAP) has been effectively used to compare the dynamics of wild-type and mutant KIF22 localization . In interphase nuclei, KIF22-GFP signal typically recovers completely (97±3% of pre-bleaching intensity) within 220 seconds, indicating a dynamic pool of KIF22-GFP . Similar high recovery percentages were measured in cells expressing KIF22-GFP with pathogenic mutations (R149Q: 100±6%; V475G: 103±7%) .

For live-cell imaging of KIF22 during mitosis, inducible expression systems of fluorescently tagged KIF22 have been successfully employed. HeLa-Kyoto cell lines with doxycycline-inducible expression of KIF22-GFP allow visualization of protein dynamics throughout cell division . To ensure physiologically relevant observations, expression levels should be carefully controlled, as KIF22-GFP expression at approximately two- to threefold higher than endogenous levels has been used in published research .

When studying mutant forms of KIF22, siRNA knockdown of endogenous protein (achieving approximately 87% reduction) combined with expression of siRNA-resistant KIF22-GFP constructs provides a clean system to observe mutant protein behavior without interference from wild-type protein .

How do pathogenic mutations in KIF22 affect experimental outcomes when using antibodies?

Pathogenic mutations in KIF22 present specific challenges for antibody-based research that must be considered when designing experiments:

When using antibodies to study mutant KIF22:

• Epitope accessibility may be affected by conformational changes induced by mutations

• Protein interaction partners may differ between wild-type and mutant forms

• Post-translational modifications may be altered, affecting antibody recognition

• Fixation methods may differentially preserve epitopes in mutant versus wild-type protein

To address these challenges, researchers should:

• Use multiple antibodies recognizing different epitopes

• Compare results from live-cell imaging with fixed-cell immunofluorescence

• Include both wild-type and mutant controls in all experiments

• Consider functional assays alongside localization studies to correlate structure with function

What are the optimal approaches for studying KIF22's role in cell cycle regulation?

KIF22 plays critical roles in cell cycle progression, particularly during mitosis, requiring specialized methodologies to properly assess its function:

For cell proliferation analysis, researchers have successfully used cell viability assays such as CCK8 to measure growth rates in control versus KIF22-knockdown or mutant cells . These assays have demonstrated that loss of KIF22 function significantly reduces proliferation rates in both cell lines and primary cells .

Cell cycle analysis can be performed using flow cytometry after propidium iodide staining, which has revealed that altering KIF22 expression primarily affects the G2/M phase . This finding correlates with KIF22's known role in mitotic spindle formation and chromosome movement.

To assess mitotic progression specifically, immunostaining for mitotic markers can be employed. Ki67, a marker of cell proliferation, shows decreased expression in KIF22-knockdown cells, confirming KIF22's role in promoting cell division . Direct counting of mitotic cells in culture provides an additional quantitative measure of KIF22's impact on mitosis .

For mechanistic studies of KIF22's role in cell cycle regulation, analysis of downstream pathway components is essential. Research has demonstrated that KIF22 regulates the CDC25C/CDK1/cyclinB1 pathway in multiple myeloma cells . Western blot analysis of these pathway components after KIF22 modulation can reveal the molecular mechanisms underlying KIF22's effects on cell cycle progression.

How is KIF22 expression altered in cancer and what are the methodological considerations for studying these changes?

KIF22 expression is significantly altered in multiple cancer types, with specific methodological considerations for research:

In multiple myeloma, KIF22 expression has been associated with several clinical features, including gender (P=0.016), LDH levels (P<0.001), β2-MG levels (P=0.003), percentage of tumor cells in bone marrow (P=0.002), and poor prognosis (P<0.0001) . These associations suggest KIF22 could serve as a prognostic biomarker.

For pan-cancer analysis, studies have shown higher KIF22 expression in tumors compared to non-tumor tissues across multiple cancer types . Researchers have correlated KIF22 expression with prognosis, genomic heterogeneity, tumor stemness, neoantigen generation, and immune infiltration .

When studying KIF22 in cancer samples, researchers should consider:

• Using paired tumor and adjacent normal tissue from the same patient when possible

• Stratifying samples based on clinical parameters (stage, grade, treatment history)

• Employing multiple detection methods (IHC, qPCR, western blot) for cross-validation

• Including sufficient sample sizes to account for tumor heterogeneity

• Correlating protein expression with functional outcomes (proliferation, migration, invasion)

In bladder cancer specifically, KIF22 expression has been significantly associated with tumor stage (P=0.003) and recurrence (P=0.016) , highlighting the importance of longitudinal sampling and clinical follow-up data when designing studies.

What experimental approaches can elucidate KIF22's role in promoting cancer progression?

Multiple complementary approaches have proven effective for investigating KIF22's oncogenic functions:

For mechanism-focused investigations, chromatin immunoprecipitation (ChIP) and luciferase reporter assays have successfully demonstrated that KIF22 directly regulates gene expression by binding to promoter regions of target genes like CDC25C . These approaches can identify direct transcriptional targets of KIF22 in different cancer contexts.

In vitro functional assays should include:

• Proliferation assays (CCK8, EdU incorporation, colony formation)

• Cell cycle analysis (flow cytometry, cyclin expression)

• Migration and invasion assays (Transwell, wound healing)

• Cell death assays (Annexin V/PI staining, TUNEL)

For in vivo validation, subcutaneous xenograft models in nude mice have successfully demonstrated KIF22's role in tumor growth . These models can be further extended to include patient-derived xenografts for greater clinical relevance.

How can KIF22 antibodies be utilized in analyzing the role of KIF22 in developmental disorders?

KIF22 has been implicated in developmental disorders, particularly those affecting skeletal development, requiring specialized antibody-based approaches:

Point mutations in KIF22 affect chondrocyte proliferation and subsequent matrix synthesis, contributing to skeletal abnormalities . When investigating developmental roles of KIF22, researchers should consider:

• Developmental timing: KIF22 expression changes throughout development, with particularly important roles during periods of rapid growth and differentiation.

• Tissue-specific effects: Focus on growth plate cartilage, where KIF22 is highly expressed in the proliferative zone of chondrocytes .

• Matrix production assessment: Alcian blue staining for proteoglycans and qPCR for extracellular matrix components (Col2a1, Acan) can reveal how KIF22 dysfunction impacts matrix synthesis .

• Cell type-specific analyses: Primary chondrocytes from wild-type versus KIF22 mutant mice show distinct phenotypes, including reduced proliferation (measured by CCK8 assays) and decreased Ki67 positivity .

• Differentiation dynamics: KIF22's impact on cell differentiation can be assessed using ATDC5 chondrogenic cells treated with insulin-transferrin-selenium to induce differentiation, followed by matrix component analysis .

When using antibodies to study KIF22 in developmental contexts, careful attention to tissue processing is essential, as fixation conditions can significantly impact epitope accessibility in developing tissues. Additionally, co-staining with markers of cell proliferation (Ki67) and differentiation stage-specific markers provides contextual information about KIF22's role in developmental processes.

What methods are effective for studying the relationship between KIF22 and the cellular immune response?

Emerging research indicates connections between KIF22 and immune parameters, suggesting specific methodological approaches:

Pan-cancer analysis has revealed strong relationships between KIF22 expression and immunomodulators, chemokines, and immune infiltration . Additionally, KIF22 methylation status shows significant correlations with immune parameters . To investigate these relationships, researchers should consider:

• Immune infiltration analysis: Correlation of KIF22 expression with immune cell population markers using techniques such as:

  • Immunohistochemistry with immune cell-specific markers

  • Flow cytometry of tumor-infiltrating lymphocytes

  • Computational deconvolution of bulk RNA-seq data

  • Single-cell RNA sequencing for high-resolution immune profiling

• Cytokine/chemokine profiling: Assessment of secreted factors using:

  • Multiplex ELISA

  • Cytokine arrays

  • RNA-seq for expression analysis

  • Mass spectrometry-based proteomics

• Epigenetic regulation: Investigation of KIF22 methylation status using:

  • Bisulfite sequencing

  • Methylation-specific PCR

  • Chromatin immunoprecipitation followed by sequencing (ChIP-seq)

• Functional immune assays:

  • Co-culture systems with immune and cancer cells

  • T cell activation assays

  • Immune cell migration assays

  • Cytotoxicity assays

KIF22 interaction and coexpression networks have been shown to involve processes related to antigen processing and presentation , suggesting direct links to immune function that warrant further investigation using the methodologies outlined above.

What are the critical validation steps for KIF22 antibodies in research applications?

Proper validation of KIF22 antibodies is essential for reliable research outcomes and should include:

• Specificity validation:

  • Western blot analysis showing a single band at the expected molecular weight (approximately 75 kDa)

  • Complete loss of signal in KIF22 knockout cell lines, as demonstrated with anti-KIF22 antibody [EP2748] in HEK-293T KIF22 knockout cells

  • Peptide competition assays to confirm epitope specificity

  • siRNA knockdown showing corresponding reduction in signal intensity

• Application-specific validation:

  • For immunohistochemistry: Testing different fixation protocols and antigen retrieval methods

  • For immunofluorescence: Confirming expected subcellular localization (both cytoplasmic and nuclear distribution)

  • For western blot: Optimizing protein extraction methods to preserve KIF22

  • For ChIP: Validating antibody efficiency in immunoprecipitating chromatin-bound KIF22

• Cross-reactivity assessment:

  • Testing in multiple species if cross-reactivity is claimed

  • Evaluating potential cross-reactivity with closely related kinesin family members

  • Confirming signal in tissues known to express KIF22 (e.g., growth plate cartilage)

• Reproducibility verification:

  • Testing different antibody lots

  • Comparing results across different detection methods

  • Ensuring consistent results across different cell lines or tissue types

Rigorous validation following these steps ensures that experimental outcomes can be confidently attributed to KIF22-specific effects rather than antibody artifacts.

What are the optimal protocols for immunoprecipitation of KIF22 for protein interaction studies?

Effective immunoprecipitation of KIF22 requires careful optimization to preserve protein-protein interactions:

For chromatin immunoprecipitation (ChIP) to study KIF22's DNA-binding activities, researchers have successfully used this approach to demonstrate that KIF22 directly regulates gene expression by binding to promoter regions of target genes . When performing KIF22 ChIP:

• Crosslinking conditions: 1% formaldehyde for 10 minutes at room temperature is typically effective

• Sonication parameters: Optimize to achieve chromatin fragments of 200-500 bp

• Antibody selection: Use ChIP-validated KIF22 antibodies recognizing epitopes that remain accessible when KIF22 is bound to DNA

• Controls: Include IgG control and input samples

• Washing stringency: Balance between preserving specific interactions and reducing background

For co-immunoprecipitation to identify KIF22 protein interaction partners:

• Lysis conditions: Use gentle lysis buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate with protease inhibitors)

• Antibody coupling: Consider covalent coupling to beads to prevent antibody leaching

• Bead selection: Protein A/G beads work well for rabbit monoclonal antibodies like EP2748

• Elution strategy: Gradient elution or competition with peptides can preserve complex integrity

• Downstream analysis: Mass spectrometry to identify novel interaction partners

When studying cell cycle-dependent interactions, synchronization of cells (using nocodazole for M-phase or double thymidine block for S-phase) prior to immunoprecipitation can reveal phase-specific protein complexes involving KIF22.

What factors influence the successful use of KIF22 antibodies in fluorescence microscopy?

Optimizing KIF22 antibody use in fluorescence microscopy requires attention to several critical factors:

• Fixation method:

  • Paraformaldehyde (4%) preserves most epitopes while maintaining cellular architecture

  • Methanol fixation may better preserve microtubule structures for co-localization studies

  • Cold methanol:acetone (1:1) can improve nuclear epitope accessibility

• Permeabilization:

  • 0.1-0.5% Triton X-100 for 5-10 minutes is typically effective

  • For membrane-associated fractions, gentler detergents like saponin (0.1%) may be preferable

• Blocking conditions:

  • 3-5% BSA or 5-10% normal serum (species-matched to secondary antibody)

  • Include 0.1% Triton X-100 to reduce non-specific binding

• Antibody dilution and incubation:

  • Optimal dilutions must be determined empirically (typically 1:100-1:1000)

  • Overnight incubation at 4°C often yields better signal-to-noise ratio than shorter incubations

• Counter-staining:

  • DAPI for nuclear visualization

  • Anti-tubulin antibodies to visualize microtubules and mitotic spindles

  • Cell cycle markers (e.g., phospho-histone H3) to identify mitotic cells

• Mounting media:

  • Anti-fade reagents to prevent photobleaching during image acquisition

  • Hardening mounting media for long-term storage of samples

Studies examining KIF22 localization during different cell cycle phases have successfully employed these approaches to demonstrate its dynamic distribution patterns, particularly during mitosis . For high-resolution imaging of KIF22 at specific subcellular structures, super-resolution techniques such as structured illumination microscopy (SIM) or stimulated emission depletion (STED) microscopy may provide valuable insights beyond conventional confocal microscopy.

What emerging technologies might enhance KIF22 antibody applications in research?

Several cutting-edge technologies show promise for advancing KIF22 research:

• Proximity labeling approaches:

  • BioID or TurboID fusion with KIF22 to identify proximal proteins

  • APEX2-based proximity labeling for temporally controlled interaction mapping

  • These approaches can reveal transient interactions during specific phases of cell division

• Super-resolution microscopy:

  • STORM/PALM for nanoscale visualization of KIF22 dynamics

  • Lattice light-sheet microscopy for rapid 3D imaging with reduced phototoxicity

  • Correlative light and electron microscopy (CLEM) to contextualize KIF22 localization

• Single-molecule tracking:

  • Photoactivatable fluorescent proteins fused to KIF22 for tracking individual molecules

  • High-speed imaging to capture rapid dynamics during chromosome movement

  • Multi-color imaging to simultaneously track KIF22 and interaction partners

• Engineered antibodies:

  • Nanobodies against KIF22 for live-cell imaging with minimal perturbation

  • Bi-specific antibodies to simultaneously target KIF22 and interacting proteins

  • Split-fluorescent protein complementation for visualization of specific protein interactions

• CRISPR-based genomic tagging:

  • Endogenous tagging of KIF22 to avoid overexpression artifacts

  • Knock-in of specific mutations associated with pathogenic conditions

  • Optogenetic control elements for temporally regulated KIF22 function

These technologies will allow researchers to address remaining questions about KIF22 function with unprecedented spatial and temporal resolution, particularly in complex processes like chromosome segregation where KIF22 plays critical roles .

How might KIF22 antibodies contribute to therapeutic development for KIF22-associated disorders?

KIF22 antibodies have significant potential for therapeutic development through several avenues:

• Diagnostic applications:

  • Immunohistochemical evaluation of KIF22 expression in cancer biopsies for patient stratification

  • Development of companion diagnostics to identify patients likely to respond to KIF22-targeted therapies

  • Monitoring treatment response through serial KIF22 expression analysis

• Therapeutic target validation:

  • Use of KIF22 antibodies to confirm target engagement in preclinical models

  • Correlation of KIF22 inhibition with phenotypic outcomes in disease models

  • Identification of patient subgroups with KIF22-dependent disease mechanisms

• Drug development tools:

  • High-throughput screening assays using KIF22 antibodies to identify compounds disrupting KIF22 function

  • Competitive binding assays to discover molecules that interfere with KIF22-protein or KIF22-DNA interactions

  • Structure-guided drug design targeting specific domains recognized by well-characterized antibodies

• Therapeutic antibody engineering:

  • Development of function-blocking antibodies targeting critical KIF22 domains

  • Intrabodies directed against KIF22 for intracellular targeting

  • Antibody-drug conjugates delivering cytotoxic payloads to KIF22-overexpressing cells